FM, Roche and DIAN col­lab­o­rate for Per­son­al­ized Can­cer Care in China

BioSpectrum (Asia) - - Company News -

Foun­da­tion Medicine, Inc. (FM), F. Hoff­mann-La Roche Ltd (Roche) and DIAN Di­ag­nos­tics Group, Co., Ltd. (DIAN), have an­nounced a three-party col­lab­o­ra­tion to in­te­grate Foun­da­tion Medicine’s com­pre­hen­sive ge­nomic pro­fil­ing (CGP) as­says into clinical pa­tient care in main­land China.

Un­der the col­lab­o­ra­tion, DIAN, a leader in the devel­op­ment and sup­ply of Chi­nese med­i­cal di­ag­nos­tic prod­ucts and ser­vices, be­comes the ex­clu­sive clinical se­quenc­ing part­ner in China for Foun­da­tionOne, Foun­da­tionACT and Foun­da­tionOneHeme, en­abling the de­liv­ery of per­son­al­ized can­cer care for pa­tients. Roche main­tains com­mer­cial ex­clu­siv­ity for Foun­da­tion Medicine’s molec­u­lar in­for­ma­tion prod­ucts in China, and in co­op­er­a­tion with DIAN con­tin­ues its cur­rent in-county ac­tiv­i­ties to sup­port the broad in­te­gra­tion of CGP into clinical care.

DIAN is one of the lead­ing in­de­pen­dent med­i­cal lab­o­ra­to­ries in China and is ded­i­cated to in­no­va­tion in di­ag­nos­tic test­ing plat­forms. Im­por­tantly, DIAN is one of the first com­mer­cial lab­o­ra­to­ries ap­proved by the Na­tional Health Com­mis­sion of China to re­ceive a next gen­er­a­tion se­quenc­ing (NGS) pilot license for can­cer di­ag­nos­tics. DIAN’s di­ag­nos­tic net­work stretches to more than 30 lab­o­ra­to­ries, cov­er­ing al­most all of main­land China, pro­cess­ing more than 100,000 clinical sam­ples per day. To ad­vance clinical di­ag­nos­tics in China, DIAN has also es­tab­lished pre­ci­sion treat­ment cen­tres with med­i­cal in­sti­tu­tions and hos­pi­tals.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.